In Restless Legs Syndrome, where is dopamine excess present and where is dopamine reuptake reduced?

Dopamine Dysregulation in Restless Legs Syndrome

In RLS, there is excess dopamine in the synaptic space of the striatum (particularly the putamen), while dopamine reuptake via the dopamine transporter (DAT) is paradoxically increased rather than reduced, creating a complex state of dopaminergic dysregulation rather than simple deficiency.

Synaptic Dopamine Excess

The most direct evidence demonstrates increased synaptic dopamine concentrations in the putamen of RLS patients 1. This finding emerged from PET studies showing:

• Lower D2 receptor binding potential (D2R-BP) in the putamen and caudate, which—given unchanged receptor density (β-max) and affinity (K-d)—indicates elevated synaptic dopamine competing with the radioligand 1
• The posterior putamen specifically shows this pattern even in dopaminergic-naive RLS patients 1
• Stroke-related RLS cases confirm increased dopaminergic tone in the ipsilateral putamen following caudate nucleus infarction 2

Dopamine Transporter Function

Contrary to what might be expected with excess synaptic dopamine, DAT density is actually increased in moderate-to-severe RLS:

• DAT availability is elevated in the caudate, posterior putamen, and entire striatum of elderly RLS patients with moderate-to-moderately severe disease 3
• This represents a compensatory upregulation attempting to clear excess synaptic dopamine 3
• The increased transporter density paradoxically coexists with the elevated synaptic dopamine, suggesting the reuptake mechanism is overwhelmed or dysfunctional despite increased transporter presence 3

Regional Specificity

The dopaminergic abnormalities show clear anatomical patterns:

• Substantia nigra and thalamus demonstrate decreased iron alongside relative dopamine excess 4
• The putamen (particularly posterior) is the primary site of measurable synaptic dopamine elevation 1
• Presynaptic dopaminergic activity is increased, contributing to the synaptic excess 1

Clinical Implications

This dopaminergic dysregulation explains why:

• Low-dose dopamine agonists target presynaptic D2 short receptors (D2SR) and provide initial benefit 5
• Higher doses activate postsynaptic striatal D3 receptors forming heteromers with D1 receptors, leading to augmentation (worsening of symptoms) 5
• The 2025 AASM guidelines now conditionally recommend against dopamine agonists as first-line therapy due to augmentation risk (7-10% annual incidence) 6, 7
• Prior dopaminergic treatment induces pathophysiological changes that impair future responses to both dopaminergic and non-dopaminergic therapies, even before clinical augmentation appears 8

Pathophysiological Context

The dopamine excess occurs within a broader context of brain iron deficiency in the same regions 4, 7. This iron-dopamine interaction likely drives the core pathophysiology, though the exact mechanism producing RLS symptoms remains incompletely understood 6, 4.